1. EFFECT OF SIMVASTATIN ON MARKERS OF CARDIOVASCULAR RISK
- Author
-
N. V. Perova, Sokolov Ei, V. A. Metel'skaya, and G. N. Shchukina
- Subjects
Oncology ,Drug ,medicine.medical_specialty ,Statin ,medicine.drug_class ,media_common.quotation_subject ,RM1-950 ,statins ,chemistry.chemical_compound ,cardiovascular disease ,Internal medicine ,Hyperlipidemia ,Medicine ,risk factors ,hyperlipidemia ,simvastatin ,Diseases of the circulatory (Cardiovascular) system ,Pharmacology (medical) ,cardiovascular diseases ,triglycerides ,media_common ,business.industry ,Cholesterol ,nutritional and metabolic diseases ,cholesterol ,medicine.disease ,Clinical Practice ,lipoproteins ,Endocrinology ,chemistry ,Simvastatin ,RC666-701 ,lipids (amino acids, peptides, and proteins) ,Therapeutics. Pharmacology ,atherosclerosis ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Current views on the efficacy criteria of hyperlipidaemia treatment with statins are considered. Requirements for generics of one of the widely used statin, simvastatin, are discussed. Data of several studies of Simvastol (generic simvastatin) and results of its use for hyperlipidaemia treatment in clinical practice are presented. The results of the studies demonstrate high efficacy of this product as a cholesterol-lowering drug which has pleiotropic effects involving into the atherosclerosis progression.
- Published
- 2016